Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, T-Cell

Explore clinical trials studying Lymphoma, T-Cell. Study availability and eligibility vary by location and protocol.

185 public trials 53 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, T-Cell trial results

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

NCT03833180

Conditions
Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +49 more
Locations
  • City of Hope ( Site 0010) Duarte, California, United States
  • University of California - San Diego ( Site 0003) La Jolla, California, United States
  • UCLA Hematology & Oncology ( Site 0007) Los Angeles, California, United States
  • University of Nebraska Medical Center ( Site 0006) Omaha, Nebraska, United States
View all 14 locations
View Trial Details
Completed

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

NCT02561273

Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Enteropathy-Associated T-Cell Lymphoma, +21 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • University of Colorado Cancer Center, Anschutz Cancer Pavilion Aurora, Colorado, United States
  • Emory University/Winship Cancer Institute Atlanta, Georgia, United States
View Trial Details
Completed

ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy

NCT04121507

Conditions
Aggressive Non-hodgkin Lymphoma (aNHL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation Berlin, Brandenburg, Germany
  • Klinikum Augsburg, Medizinische Klinik II Augsburg, Germany
  • Medizinisches Universitätsklinikum Bochum, Germany
  • Klinikum Chemnitz gGmbH Chemnitz, Germany
View all 13 locations
View Trial Details
Completed

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

NCT03770000

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • USC/Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California, Hellen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • University of Miami-Sylvester Comprehensive Cancer Center Miami, Florida, United States
View all 15 locations
View Trial Details

Related conditions